YuanMing Capital
China's CF PharmTech raises $50m Series F
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Biotech player Ascentage gains on debut after $53m HK IPO
Ascentage Pharma saw its share price surge 57% during the first day of trading in Hong Kong before closing up 9.9%, following a heavily oversubscribed HK$416.6 million ($53 million) IPO.
Chinese investors lead round for US influenza specialist
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.
China’s Ascentage Pharma files for HK IPO
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
China's Ascentage Pharma gets $150m in Series C funding
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.